Pemazyre

Generic name: Pemigatinib
Drug class: Multikinase inhibitors

Usage of Pemazyre

Pemazyre is a kinase inhibitor that blocks the action of protein kinases.

Pemazyre a prescription medicine used in adults to treat bile duct cancer (cholangiocarcinoma) that has spread to other parts of the body (metastatic) or cannot be removed with surgery. This medicine is usually given after your cancer has been treated with another medicine, and when the cancer has a certain type of abnormal FGFR2 gene. Your doctor will test you for this gene.

Pemazyre was approved by the US Food and Drug Administration (FDA) for bile duct cancer on an "accelerated" basis. In clinical studies, some people responded to Pemazyre, but further studies are needed.

Pemazyre is also used in adults to treat a type of blood cancer called myeloid/lymphoid neoplasms (MLNs) when the cancer has come back or did not respond to treatment, and when the cancer has a certain type of abnormal FGFR1 gene. Your doctor will test you for this gene.

It is not known if this medicine is safe and effective in children.

Pemazyre side effects

Get emergency medical help if you have signs of an allergic reaction to Pemazyre: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

eye problems--eye pain or redness, dry or puffy eyes, watery eyes, your eyes may be more sensitive to light;

vision changes--blurred vision, seeing black spots or "floaters," or seeing flashes of light; or

high phosphate levels in your blood--muscle cramps, numbness, tingly feeling around your mouth.

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

Common Pemazyre side effects in cholangiocarcinoma may include:

hair loss;

diarrhea;

problems with your fingernails or toenails;

feeling tired;

changes in your sense of taste;

nausea, vomiting, loss of appetite;

constipation;

mouth sores, dry mouth;

dry eyes;

joint pain, back pain;

stomach-area (abdominal) pain;

high or low phosphate levels in your blood;

dry skin.

Common Pemazyre side effects in myeloid/lymphoid neoplasms may include:

problems with your fingernails or toenails;

hair loss;

mouth sores, dry mouth;

diarrhea;

dry eyes;

feeling tired;

anemia;

stomach-area (abdominal) pain;

rash;

constipation;

nose bleeds;

blurry vision, disorder of the retina;

pain in feet or hands;

loss of appetite;

dry skin;

indigestion;

back pain;

nausea;

swelling in feet, legs, hands, or arms

dizziness.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Pemazyre

To make sure Pemazyre is safe for you, tell your doctor if you have ever had:

problems with your eyes;

vision problems; or

trouble swallowing pills.

You may need to have a negative pregnancy test before starting this treatment.

Both men and women using Pemazyre should use effective birth control to prevent pregnancy. Pemazyre can harm an unborn baby or cause a miscarriage if the mother or father is using this medicine.

Keep using birth control for at least 1 week after your last dose. Tell your doctor right away if a pregnancy occurs while either the mother or the father is using Pemazyre.

Do not breastfeed while using this medicine, and for at least 1 week after your last dose.

Relate drugs

How to use Pemazyre

Usual Adult Dose for Cholangiocarcinoma of biliary tract:

13.5 mg orally once daily for 14 consecutive days followed by 7 days off therapy, in 21-day cycles until disease progression or unacceptable toxicity Use: for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.

Usual Adult Dose for Lymphoma:

13.5 mg orally once daily Duration of therapy: Until disease progression or unacceptable toxicity occurs. Comments: -FGFR 1 rearrangement positivity status must be known prior to the initiation of therapy. -Assessment for FGFR 1 rearrangement positivity in tumor specimen should be performed with an appropriate diagnostic test. Use: For the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement

Usual Adult Dose for Multiple Myeloma:

Warnings

Follow all directions on your medicine label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use.

What other drugs will affect Pemazyre

Sometimes it is not safe to use certain medications at the same time. Some drugs can affect your blood levels of other drugs you take, which may increase side effects or make the medications less effective.

Other drugs may affect Pemazyre, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.